Adverse perinatal outcomes associated with prenatal exposure to protease-inhibitor-based versus non-nucleoside reverse transcriptase inhibitor-based antiretroviral combinations in pregnant women with HIV infection: a systematic review and meta-analysis
Background About 1.3 million pregnant women lived with HIV and were eligible to receive antiretroviral therapy (ART) worldwide in 2021. The World Health Organization recommends protease inhibitors (PI)-based regimen as second or third-line during pregnancy. With remaining pregnant women exposed to P...
Saved in:
Main Authors: | Laura Saint-Lary (Author), Justine Benevent (Author), Christine Damase-Michel (Author), Christophe Vayssière (Author), Valériane Leroy (Author), Agnès Sommet (Author) |
---|---|
Format: | Book |
Published: |
BMC,
2023-01-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Integrase inhibitor drugs during pregnancy and congenital anomalies: A case/non‐case study from the global pharmacovigilance database VigiBase®
by: Laura Saint‐Lary, et al.
Published: (2024) -
Updated guidelines for the use of rifamycins for the treatment of tuberculosis in HIV-infected patients taking protease inhibitors or non-nucleoside reverse transcriptase inhibitors
by: Editorial Office
Published: (2004) -
Effect of non-nucleoside reverse transcriptase inhibitors and protease inhibitors on serum levels of myeloperoxidase and C-reactive protein in HIV-infected individuals
by: Danielle Cristyane Kalva Borato, et al.
Published: (2022) -
Development of non-nucleoside reverse transcriptase inhibitors (NNRTIs): our past twenty years
by: Chunlin Zhuang, et al.
Published: (2020) -
Non-Nucleoside Reverse Transcriptase Inhibitors Join Forces with Integrase Inhibitors to Combat HIV
by: Daniel M. Himmel, et al.
Published: (2020)